Evidence map›Paper›PMID 31011151›Full record

ArticleTranslational psychiatry2019

Proteomic analysis of lymphoblastoid cell lines from schizophrenic patients.

Akira Yoshimi, Shinnosuke Yamada, Shohko Kunimoto, Branko Aleksic, Akihiro Hirakawa, Mitsuki Ohashi, Yurie Matsumoto, Kazuhiro Hada, Norimichi Itoh, Yuko Arioka and 11 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 1 country.

Akira YoshimiDivision of Clinical Sciences and Neuropsychopharmacology, Faculty and Graduate School of Pharmacy, Meijo University, Nagoya, 468-8503, Japan.ORCID http://orcid.org/0000-0001-6636-7970
Shinnosuke YamadaDivision of Clinical Sciences and Neuropsychopharmacology, Faculty and Graduate School of Pharmacy, Meijo University, Nagoya, 468-8503, Japan.
Shohko KunimotoDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
Branko AleksicDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan. branko@med.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0001-8982-4580
Akihiro HirakawaDepartment of Biostatistics and Bioinformatics, Graduate School of Medicine, University of Tokyo, Tokyo, 113-0033, Japan.
Mitsuki OhashiDivision of Clinical Sciences and Neuropsychopharmacology, Faculty and Graduate School of Pharmacy, Meijo University, Nagoya, 468-8503, Japan.
Yurie MatsumotoDivision of Clinical Sciences and Neuropsychopharmacology, Faculty and Graduate School of Pharmacy, Meijo University, Nagoya, 468-8503, Japan.
Kazuhiro HadaDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
Norimichi ItohDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
Yuko AriokaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
Hiroki KimuraDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
Itaru KushimaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
Yukako NakamuraDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
Tomoko ShiinoDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.ORCID http://orcid.org/0000-0002-8750-0854
Daisuke MoriDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.ORCID http://orcid.org/0000-0002-9072-2546
Satoshi TanakaDepartment of Psychiatry, Nagoya University Hospital, Nagoya, 466-8550, Japan.ORCID http://orcid.org/0000-0002-7101-0690
Shuko HamadaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
Yukihiro NodaDivision of Clinical Sciences and Neuropsychopharmacology, Faculty and Graduate School of Pharmacy, Meijo University, Nagoya, 468-8503, Japan.
Taku NagaiDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
Kiyofumi YamadaDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
Norio OzakiDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.ORCID http://orcid.org/0000-0002-7360-4898
Nagoya University Hospital · JPNagoya University · JPMeijo University · JPNational Center of Neurology and Psychiatry · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although a number of studies have identified several convincing candidate genes or molecules, the pathophysiology of schizophrenia (SCZ) has not been completely elucidated. Therapeutic optimization based on pathophysiology should be performed as early as possible to improve functional outcomes and prognosis; to detect useful biomarkers for SCZ, which reflect pathophysiology and can be utilized for timely diagnosis and effective therapy. To explore biomarkers for SCZ, we employed fluorescence two-dimensional differential gel electrophoresis (2D-DIGE) of lymphoblastoid cell lines (LCLs) (1st sample set: 30 SCZ and 30 CON). Differentially expressed proteins were sequenced by liquid chromatography tandem-mass spectrometry (LC-MS/MS) and identified proteins were confirmed by western blotting (WB) (1st and 2nd sample set: 60 SCZ and 60 CON). Multivariate logistic regression analysis was performed to identify an optimal combination of biomarkers to create a prediction model for SCZ. Twenty protein spots were differentially expressed between SCZ and CON in 2D-DIGE analysis and 22 unique proteins were identified by LC-MS/MS. Differential expression of eight of 22 proteins was confirmed by WB. Among the eight candidate proteins (HSPA4L, MX1, GLRX3, UROD, MAPRE1, TBCB, IGHM, and GART), we successfully constructed logistic regression models comprised of 4- and 6-markers with good discriminative ability between SCZ and CON. In both WB and gene expression analysis of LCL, MX1 showed reproducibly significant associations. Moreover, Mx1 and its related proinflamatory genes (Mx2, Il1b, and Tnf) were also up-regulated in poly I:C-treated mice. Differentially expressed proteins might be associated with molecular pathophysiology of SCZ, including dysregulation of immunological reactions and potentially provide diagnostic and prognostic biomarkers.

Indexed as

ProteomicsAnimalsBiomarkersBlotting, WesternCell LineChromatography, LiquidElectrophoresis, Gel, Two-DimensionalFemaleHumansLogistic ModelsMaleMiceMultivariate AnalysisPrognosisSchizophreniaTandem Mass SpectrometryBiomarkers

Identifiers

PMID31011151
PMCPMC6476876
OpenAlexW2937013593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.